Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD

20.73  -0.86 (-3.98%)

After market: 20.95 +0.22 (+1.06%)

Fundamental Rating

3

Overall DNLI gets a fundamental rating of 3 out of 10. We evaluated DNLI against 572 industry peers in the Biotechnology industry. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability. DNLI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DNLI has reported negative net income.
DNLI had a negative operating cash flow in the past year.
In the past 5 years DNLI reported 4 times negative net income.
DNLI had negative operating cash flow in 4 of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

1.2 Ratios

DNLI has a Return On Assets of -29.40%. This is in the better half of the industry: DNLI outperforms 69.45% of its industry peers.
The Return On Equity of DNLI (-32.42%) is better than 77.09% of its industry peers.
Industry RankSector Rank
ROA -29.4%
ROE -32.42%
ROIC N/A
ROA(3y)-18.54%
ROA(5y)-17.38%
ROE(3y)-25.19%
ROE(5y)-23.88%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30 -40 -50

1.3 Margins

DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DNLI has been increased compared to 1 year ago.
The number of shares outstanding for DNLI has been increased compared to 5 years ago.
There is no outstanding debt for DNLI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

DNLI has an Altman-Z score of 11.34. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
DNLI has a better Altman-Z score (11.34) than 87.92% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DNLI is not too dependend on debt financing.
DNLI's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. DNLI outperforms 44.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.34
ROIC/WACCN/A
WACC9.44%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 9.98 indicates that DNLI has no problem at all paying its short term obligations.
The Current ratio of DNLI (9.98) is better than 79.93% of its industry peers.
DNLI has a Quick Ratio of 9.98. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
DNLI has a better Quick ratio (9.98) than 80.28% of its industry peers.
Industry RankSector Rank
Current Ratio 9.98
Quick Ratio 9.98
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

5

3. Growth

3.1 Past

DNLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -194.85%.
The Revenue for DNLI has decreased by -100.00% in the past year. This is quite bad
The Revenue has been growing by 20.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-194.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-0.52%
Revenue growth 5Y20.67%
Sales Q2Q%-100%

3.2 Future

DNLI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
DNLI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.97% yearly.
EPS Next Y-155.51%
EPS Next 2Y-69.07%
EPS Next 3Y-32.63%
EPS Next 5Y13.45%
Revenue Next Year-97.36%
Revenue Next 2Y-67.94%
Revenue Next 3Y-20.32%
Revenue Next 5Y13.97%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

DNLI's earnings are expected to decrease with -32.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.07%
EPS Next 3Y-32.63%

More info and screens

0

5. Dividend

5.1 Amount

DNLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (2/21/2025, 8:14:14 PM)

After market: 20.95 +0.22 (+1.06%)

20.73

-0.86 (-3.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners91.51%
Inst Owner Change-97.55%
Ins Owners4.61%
Ins Owner Change0.39%
Market Cap2.98B
Analysts87.5
Price Target41.02 (97.88%)
Short Float %5.95%
Short Ratio8.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.55%
Min EPS beat(2)-0.5%
Max EPS beat(2)15.61%
EPS beat(4)1
Avg EPS beat(4)0.37%
Min EPS beat(4)-8.8%
Max EPS beat(4)15.61%
EPS beat(8)4
Avg EPS beat(8)36.93%
EPS beat(12)5
Avg EPS beat(12)21.54%
EPS beat(16)6
Avg EPS beat(16)1506.22%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)193.84%
Revenue beat(12)4
Avg Revenue beat(12)123.36%
Revenue beat(16)5
Avg Revenue beat(16)99.97%
PT rev (1m)-5.97%
PT rev (3m)-1.36%
EPS NQ rev (1m)4.28%
EPS NQ rev (3m)-10.31%
EPS NY rev (1m)3.08%
EPS NY rev (3m)-2.34%
Revenue NQ rev (1m)-3.46%
Revenue NQ rev (3m)-12.51%
Revenue NY rev (1m)51.3%
Revenue NY rev (3m)-49.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-2.86
EYN/A
EPS(NY)-3.09
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0
BVpS9.16
TBVpS9.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.4%
ROE -32.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.54%
ROA(5y)-17.38%
ROE(3y)-25.19%
ROE(5y)-23.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.98
Quick Ratio 9.98
Altman-Z 11.34
F-Score1
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)115.78%
Cap/Depr(5y)121.51%
Cap/Sales(3y)12.59%
Cap/Sales(5y)21.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-155.51%
EPS Next 2Y-69.07%
EPS Next 3Y-32.63%
EPS Next 5Y13.45%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-0.52%
Revenue growth 5Y20.67%
Sales Q2Q%-100%
Revenue Next Year-97.36%
Revenue Next 2Y-67.94%
Revenue Next 3Y-20.32%
Revenue Next 5Y13.97%
EBIT growth 1Y-197.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-184.43%
EBIT Next 3Y-36.14%
EBIT Next 5Y12.36%
FCF growth 1Y-48.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.64%
OCF growth 3YN/A
OCF growth 5YN/A